A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Sponsor: Xencor, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS3456
U.S. Govt. ID: NCT03752398
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The primary purposes of this research study are to learn the safety and tolerability of the investigational drug, XmAb23104, for up to eight dose levels; to see if XmAb23104 works in treating tumors like the one that you have, and to see if side effects from XmAb23104 occur in order to find the maximum tolerated dose or recommended dose for treating your type of tumor. XmAb23104 is an investigational drug that is designed to activate your own cells to kill your tumor. XmAb23104 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.
This study is closed
Mark Stein, MD
Do You Qualify?
Has your cancer progressed after treatment or do you have no appropriate available therapies? Yes No
Do you have an autoimmune disease? Yes No
Are you able to perform everyday actions independently? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator